02/2025
Cancer vaccine from Austria: “Approval by 2029 realistic” Link: Krebsimpfstoff aus Österreich: "Zulassung bis 2029…
02/2025
Science that gives hope. New cancer treatment options are presented on World Cancer Day in…
01/2025
Our Head of R&D and CMO Ingrid Rauter met with Krems Bioanalytics to discuss key R&D projects for the…
01/2025
After a long time of research in the field of oncology immunotherapy major breakthrough developments…
12/2024
Our Head of R&D and Chief Medical Officer Ingrid Rauter and our CEO Martin Munte…
11/2024
We are very proud to share this article from the Austrian newspaper Kurier, in which the…
11/2024
Excellent review article on difficult to treat immunologic targets. Future tumour vaccine developments must also…
11/2024
Our Head of Research and Development, Dr Ingrid Rauter, talks in the Swiss magazine Sprechstunde…
10/2024
Are therapeutic cancer vaccines the next generation in oncology? Current state of the art well…
09/2024
On tour for Vaccentis in Germany and Austria. Great opportunity to visit offices and labs…
08/2024
After a great Swiss National Day on August 1, we are delighted to share an…
06/2024
On 24 June, Vaccentis held a cross-functional Advisory Board under the leadership of our Head…
06/2024
The Annual General Meeting of Vaccentis AG took place on 20 June 2024 at the offices of…
05/2024
Take a look at a scientific report on the possibilities for treating renal cell cancer.…
05/2024
Our CEO Martin Munte had the opportunity to speak with the Vienna City Councillor for…
